DexCom (NASDAQ:DXCM) Stock Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of DexCom, Inc. NASDAQ: DXCM. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in DexCom stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

DexCom Stock Up 2.6%

DXCM stock traded up $2.25 during mid-day trading on Friday, hitting $88.99. The stock had a trading volume of 3,072,147 shares, compared to its average volume of 2,733,721. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The company has a fifty day moving average of $84.58 and a 200 day moving average of $80.41. The stock has a market capitalization of $34.89 billion, a price-to-earnings ratio of 66.41, a PEG ratio of 1.85 and a beta of 1.44.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The business's revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president owned 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,190 shares of company stock worth $2,281,732. Insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DXCM shares. Citigroup reaffirmed a "buy" rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. The Goldman Sachs Group assumed coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target for the company. Truist Financial assumed coverage on DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Morgan Stanley upped their price target on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Barclays upped their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $99.60.

Institutional Trading of DexCom

Several hedge funds have recently added to or reduced their stakes in DXCM. Private Trust Co. NA raised its holdings in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom in the 1st quarter valued at approximately $27,000. Optiver Holding B.V. acquired a new position in DexCom in the 4th quarter valued at approximately $33,000. Finally, TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.